HS-20093 shows response in lung cancers in Phase 1a/b trial
New Drug Targets Deadly Lung Cancer Cells
A Phase 1a/b trial in 306 patients with previously treated advanced solid tumors found HS-20093, a B7-H3-targeted antibody-drug conjugate, h…
A new drug attacks a specific protein on lung cancer cells, helping more than half of patients with an aggressive type while remaining safe …
Izalontamab brengitecan shows activity in pretreated NSCLC with non-classical actionable genomic alterations
For lung cancer patients who have run out of options, a new drug mix shows promise but needs more time.
This phase 1 study evaluated izalontamab brengitecan (iza-bren) in 83 patients with locally advanced or metastatic NSCLC harboring actionabl…
Lung cancer patients with limited options saw tumors shrink in 40% of cases and disease controlled in 86% using a new drug mix with manageab…
In L858R-mutated NSCLC, ICI combinations improve progression-free survival versus chemotherapy in TKI-resistant patients.
Immune Drugs Work in This Lung Cancer, But Only as a Team
This systematic review and meta-analysis evaluated immune checkpoint inhibitor (ICI)-based treatments in EGFR L858R-mutated non-small cell l…
For lung cancer patients with a specific mutation, immune drugs alone fail but work when combined with other treatments to delay progression…
First-line platinum-based chemotherapy associated with disease control and survival in recurrent NSCLC patients.
Chemotherapy Changes Your Immune Cells
This cohort study evaluated 42 patients with recurrent unresectable locally advanced or stage IV NSCLC without actionable mutations receivin…
Standard lung cancer chemotherapy can reshape the body's immune defenses instead of just destroying them, helping patients control their dis…
Concurrent TP53 and KRAS alterations show inconsistent survival impact across gastrointestinal cancers
Two Bad Genes Mean Different Things
A database analysis of multi-cancer cohorts found that concurrent TP53 and KRAS alterations were associated with significantly shorter overa…
Having two common cancer gene changes usually signals a worse outcome, but in stomach cancer, this same genetic mix actually predicts the lo…
Meta-analysis shows radiomics-based machine learning models predict recurrence risk in non-small cell lung cancer patients.
Your Lung Cancer Scan May Already Hold a Hidden Clue About Its Return
This systematic review and meta-analysis evaluated radiomics-based machine learning models for predicting recurrence risk in 7,964 patients …
Artificial intelligence can find hidden patterns in routine lung scans to predict if common lung cancer will return, giving patients a cruci…
AI-based PD-L1 scoring shows concordance with expert assessment in 333 NSCLC cases.
AI Now Reads Cancer Biopsies. Is It Better Than a Human Eye?
This cohort study evaluated concordance between AI-based PD-L1 scoring (uPath VENTANA PD-L1 Assay Algorithm) and expert pathologist assessme…
A new AI tool matches expert doctors in reading lung cancer biopsies, helping patients get faster, more consistent treatment decisions witho…
Eight-week mindfulness-based stress reduction reduced fatigue, anxiety, and depression in non-small cell lung cancer patients.
Mindfulness training helped lung cancer patients feel less tired and anxious after surgery
This randomized controlled trial evaluated an eight-week mindfulness-based stress reduction program in 80 non-small cell lung cancer patient…
An eight-week mindfulness program helped lung cancer patients feel less tired and anxious during recovery from surgery and chemotherapy.
PD-1/PD-L1 inhibitors plus anti-angiogenic TKIs improve PFS but not OS in advanced NSCLC
Does combining these lung cancer drugs extend life, or just delay disease growth?
A meta-analysis of 2,787 patients with advanced or metastatic NSCLC found that combining PD-1/PD-L1 inhibitors with multi-targeted anti-angi…
Combining lung cancer drugs slows disease growth but offers no clear survival benefit for patients with advanced non-small cell lung cancer.
SBRT shows early QoL advantage over CHRT in inoperable stage I NSCLC, but long-term scores converge
Which radiation therapy helps people with inoperable lung cancer feel better?
A phase 3 RCT of 233 patients with medically inoperable stage I NSCLC compared SBRT to CHRT. At 2 weeks, SBRT showed better global health sc…
For inoperable lung cancer, a newer radiation method offers early relief but conventional therapy catches up in overall health by two years.
Benmelstobart plus anlotinib improves progression-free survival versus pembrolizumab plus placebo in first-line PD-L1-positive advanced NSCLC.
New drug combo may extend time before cancer grows in lung patients
This randomised, controlled, phase 3 trial evaluated benmelstobart plus anlotinib versus pembrolizumab plus placebo in patients with PD-L1-p…
A new drug combo may extend the time before cancer grows in lung patients who have not yet received treatment for their advanced disease.
BACE plus tislelizumab shows activity in advanced NSCLC patients ineligible for standard care
Combination treatment shows promise for advanced lung cancer patients ineligible for standard care
A Phase II, single-arm trial in 30 patients with Stage IIIA-IIIC NSCLC who refused or were ineligible for standard treatment evaluated bronc…
A new combo treatment for advanced lung cancer patients ineligible for standard care helped 60% shrink tumors and extended survival to 15 mo…